Zenosense
has posted some solid news in the last two months on the progress of their
rapid detection sensor technology for sniffing out MRSA/SA Super-Bug
(Methicillin-resistant Staphylococcus aureus) and lung cancer from patient’s
breath. Devices whose advent could create a paradigm shift in currently costly,
time-consuming and/or dangerous testing methodologies.
Late last
month, the company was proud to report that their MRSA/SA detector prototype
successfully scored a 95% plus detection rate in clinical testing, with key
circuit board integration advancement also occurring, including a powerful
solid-state processor and low power piezoelectric (electric charge created
through applied mechanical stress on certain types of material) sampling pump.
Ongoing development of the company’s core technology has led to a simple, yet
effective design, which neatly encapsulates all the hardware and circuitry, and
yet is able to run continuously for an entire standard shift thanks to the
device’s low power consumption profile, while still incorporating a four sensor
parallel array. The MRSA/SA detector prototype does continuous sampling at a
rate of once every handful of milliseconds, rapidly testing cultured patient
headspace for key VOC (volatile organic compound) indicators, using a
sophisticated architecture that spans air injection capable of sampling a
negative vacuum, suction, data download, and a self-cleaning cycle.
Such a
device is a quantum leap beyond collecting swab samples and sending them off to
the lab for testing, a process which can take considerable time and money. Even
advanced PCR-based (polymerase chain reaction) rapid testing still requires
swabbing and sequencing. A logistically inefficient approach considering that,
despite seeming declines from 2005 CDC/JAMA figures of around 95k infections
and over 18k related MRSA fatalities, antibiotic resistant MRSA infection led
to more deaths in the U.S. alone than emphysema, HIV/AIDS, Parkinson’s disease,
and homicides combined in recent years. Despite the latest studies indicating
invasive MRSA infection and fatality rates have declined to around 80k and 11k
respectively or less, patients are twice as likely to die when they have MRSA,
compared to methicillin-treatable Staph, with hospitalized MRSA patients
costing the healthcare system as much as $4.2B a year according to an Issue
Brief from the Pew Charitable Trust.
Indeed,
broader hospital-acquired infection (HAI) prevalence and its results, as
reported by Kaiser Health News, indicate the true need for a rapid detection
device. As many as 1 in every 25 hospital patients were found to have acquired
some kind of infection according to the Kaiser study, resulting in over 75k
deaths each year. A growing elderly population of rapidly retiring Baby
Boomers, with almost 11k per day becoming eligible for retirement, are
particularly at risk given the sizeable number who are increasingly on some
form of immune-suppressing drug for conditions like alopecia, arthritis,
Crohn’s disease, M.S., psoriasis, or a recent transplant.
ZENO’s
work on applying their detection technology to lung cancer has also seen some
nice traction in October and November of this year, with the latest report out
earlier this month indicating that the company is already in advanced
pre-commercial prototyping on their lung cancer detector. The device, being
developed via Sgenia group company and ZENO partner, Zenon Biosystem, even has
advanced filtering technology that is specifically designed to target and
screen out VOC biomarkers not associated with lung cancer. Subsystem
optimization, including filtering technology using molecular sieves built right
into the layered/mixed sensor array, as well as a nanometric sensing mesh to
ensure a maximum detection footprint, has gone quite well, leading to high confidence
at ZENO that these low cost components will nevertheless achieve top line
results in the final device design.
Zenon has
even made some serious breakthroughs with novel metal oxide sensor materials
not currently commercially available anywhere else and the incorporation of a
micro gas chromatography chip, as well as quartz crystal sensor with gas
sorbent substrate, means the lung cancer detection device will likely provide
some of the best pre-detection screening, as well as highly-accurate lung cancer-associated
VOC sensing possible. Two identical pre-commercial detection devices are either
being manufactured or have already been completed as of the time of this
writing, according to the given timeline estimates. This places ZENO squarely
on-track for subsequent clinical testing and the company is currently gearing
up for a planned lung cancer detection trial in cooperation with Zenon. ZENO
could bring an extremely cost-competitive alternative to the lung cancer
detection market, offering a compelling new choice over the industry standard,
“low-dose” CT scanning, which actually increases the risk of cancer, using
around 150 to 1.1k times the radiation of a typical x-ray.
Lung
cancer is the number one cancer killer in the U.S. for both men and women, resulting
in more deaths than the next three most common cancers combined (breast, colon
and pancreatic), and is even more prevalent in women than breast cancer. ACA
data even indicates that among the 108k new cases of lung cancer in women
diagnosed each year, a staggering 66% plus will perish, throwing a bright
spotlight on the underlying demand curve for the emergence of a rapid detection
system like the one Zenosense has under development.
For more
information on Zenosense, visit: www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment